Pfizer Dodges More Sanctions In Neurontin Antitrust MDL

Law360, New York (July 7, 2011, 3:44 PM EDT) -- A magistrate judge refused Tuesday to sanction Pfizer Inc. by striking its denial that it promoted off-label uses of epilepsy drug Neurontin, the latest in a New Jersey multidistrict litigation claiming the drugmaker used patent litigation to delay generic competition.

Magistrate Judge Patty Shwartz rejected requests by the class action plaintiffs that the federal court consider their off-label use allegations as established and block Pfizer from presenting evidence or arguments to the contrary. The suit, part of the MDL, was brought by direct purchasers of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.